FinscoFinsco

Beam Therapeutics (US.BEAM)

Capital Allocation Audit · Period: 2018 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BEAM · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion101.7%→
ROE-8.1%↑
Cash Conversion-→
D/E Ratio0.22↓
Gross Margin0.0%↓
US.BEAM (Beam Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   101.7%    →
ROE               -8.1%    ↑
Cash Conversion       -    →
D/E Ratio          0.22    ↓
Gross Margin       0.0%    ↓
Key Metrics
US.BEAM (Beam Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 101.7% →
ROE -8.1% ↑
Cash Conversion - →
D/E Ratio 0.22 ↓
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies